Globavir’s PanGlob Test Receives Approval for Sales and Distribution in India
LOS ALTOS, Calif., January 25, 2017 -- Globavir Biosciences, Inc., a California-based biotechnology company developing dengue diagnostics and small molecule drugs to treat cancer and infectious diseases, has announced the approval of their PanGlob™ Dengue rRT-PCR kit from the Ministry of Health & Family Welfare in India. Globavir and its Indian distribution partner, Suyog Diagnostics Private Limited, a Mumbai-based diagnostic technologies distribution company, are working to launch the test this upcoming monsoon season (May– September) when Dengue is most prevalent and problematic.
“Diagnosing dengue is challenging because of the nature of the infection and its different serotypes,” says Globavir CEO Dr. Shalabh Gupta. “Current tests struggle to accurately diagnose dengue. The approval and distribution of PanGlob in India provides a more sensitive, accurate, and affordable test option that we believe will revolutionize the diagnosis of dengue infections in a country where dengue is a rapidly growing problem.” Globavir is also in the process of launching with Suyog in India, a multiplex test, MulGlob™, which can detect multiple pathogens, including dengue, in a single test.
“Dengue is a growing health concern in India, but suffers from the lack of accurate and affordable test options,” said Rajesh Maheshwari, President & CEO of Suyog Diagnostics Private Limited. “We are excited by the approval of the PanGlob test, and are proud to partner with Globavir to bring this test to India.”
About the PanGlob Assay
PanGlob is an rRT-PCR dengue diagnostic test with higher sensitivity than any currently available commercial test. The sensitivity of the test allows for accurate viral detection after the first five days of infection, when viral load decreases in the bloodstream, often to levels below the detection limits for many tests. This increased sensitivity is especially crucial for patients admitted during in later stages of the disease, when the risks for secondary complications such as dengue shock syndrome and hemorrhagic fever are highest. By confirming a dengue diagnosis more quickly, the proper treatment and care can be administered to mitigate and reduce the occurrence of severe forms of infection.
The original technology that led to this test was licensed from Stanford University. The test is now registered in India with the Ministry of Health & Family Welfare, and is now ready for launch in India. The test is also CE-marked and approved for sale in the European Union.
Dengue is a mosquito-borne viral infection that causes flu-like illness that can develop into a potentially lethal complication called severe dengue. According to the World Health Organization, the global incidence of dengue has grown dramatically in recent decades, with about half of the world’s population now at risk. Driven by increased travel of asymptomatic patients and the global spread of the disease-carrying mosquito, a recent estimate reports that dengue infection affects approximately 390 million patients worldwide, with nearly 100 million of these cases manifesting with consequences ranging from the painful and debilitating dengue fever to severe dengue. Dengue is endemic in more than 100 countries in the WHO regions of Africa, the Americas, the Eastern Mediterranean, South-East Asia and the Western Pacific.
About Globavir Biosciences
Globavir Biosciences, based in Los Altos, CA, is developing life-saving technologies for cancer and the diagnosis and treatment of some of the world’s most deadly viral diseases. To complement its world-class dengue diagnostic assays, Globavir is also developing GBV006, a powerful combination drug therapy, for the treatment of dengue fever.
About Suyog Diagnostics
Suyog Diagnostics Private Limited, based in India, is a supplier for the last two decades of medical equipment and diagnostics kits used in pathology, hematology, microbiology, molecular, blood banking and point of care labs. Clients include the various departments in the Ministry of Health in the Government of India, the Indian Army, the Indian Railways, medical colleges and research institutes, corporate hospitals, and labs all over India.